FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

Summary by AI BETAClose X

Bank of America Corporation has acquired financial instruments that have resulted in a change to its holdings in Faron Pharmaceuticals Oy, crossing a notification threshold on June 4, 2026. The company's total position now stands at 10.57%, comprising 0.11% in shares and voting rights and 10.46% through financial instruments, an increase from its previous notification of 9.46%. This change is due to an acquisition of financial instruments, with the total number of shares and voting rights in the issuer being 206,411,888.

Disclaimer*

Faron Pharmaceuticals Ltd | Company announcement | June 10, 2026 at 19:45:00 EEST

Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FIN-FSA)

1. Identity of the issuer:
Faron Pharmaceuticals Oy
2. Reason for the notification (please tick the appropriate box or boxes):

☐ An acquisition or disposal of shares or voting rights
☒ An acquisition or disposal of financial instruments
☐ An event changing the breakdown of shares or voting rights
☐ Other (please specify): Click here to enter text.

3. Details of person subject to the notification obligation:
Name:
Bank of America Corporation
City and country of residence:
Wilmington, DE, United States of America
4. Full name of shareholder(s) (if different from 3.):
-
5. Date on which the threshold was crossed or reached:
4.6.2026
6. Total positions of person(s) subject to the notification obligation:

% of shares and voting rights
(total of 7.A)
% of shares and voting rights through financial instruments
(total of 7.B)
Total of both in % (7.A + 7.B)Total number of shares and voting rights of issuer
Resulting situation on the date on which threshold was crossed or reached0.1110.4610.57206,411,888
Position of previous notification (if applicable)0.109.369.46

7. Notified details of the resulting situation on the date on which the threshold was crossed or reached:
A: Shares and voting rights
Class/type of
shares
ISIN code (if possible)
Number of shares and voting rights% of shares and voting rights
Direct
(SMA 9:5)
Indirect
(SMA 9:6 and 9:7)
Direct
(SMA 9:5)
Indirect
(SMA 9:6 and 9:7)
FI40001533090235,53200.11
-----
-----
SUBTOTAL A235,532
0.11



B: Financial Instruments according to SMA 9:6a
Type of financial instrumentExpiration
date
Exercise/
Conversion Period
Physical or cash settlementNumber of shares and voting rights% of shares and voting rights
Rights of Usen/an/an/a21,333,42210.34
Swaps15/10/2027n/aCash
243,327
0.12
------



SUBTOTAL B21,576,74910.46



8. Information in relation to the person subject to the notification obligation (please tick the applicable box):

☐ Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.

Full chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held starting with the ultimate controlling natural person or legal entity:
Name% of shares and voting rights% of shares and voting rights through financial instrumentsTotal of both
Bank of America Corporation


NB Holdings Corporation


BofAML Jersey Holdings Limited


BofAML EMEA Holdings 2 Limited

ML UK Capital Holdings Limited

Merrill Lynch International

Bank of America Corporation

NB Holdings Corporation

BAC North America Holding Company

Bank of America, National Association

Bank of America Corporation

NB Holdings Corporation



Bofa Securities, Inc
10.34%10.34%

9. In case of proxy voting: [name of the proxy holder] will cease to hold [% and number] voting rights as of


10. Additional information:





Done at London, United Kingdom on 5.6.2026.


UK 100

Latest directors dealings